Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

University of Alabama at Birmingham (UAB) Pediatric CBD Program

Next Previous
Trial Profile

University of Alabama at Birmingham (UAB) Pediatric CBD Program

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Expanded access

    • Most Recent Events

    • 01 Sep 2021 Results of an analysis assessing the longitudinal impact of highly purified cannabidiol on the electroencephalogram, a comparison between children and adults studies (NCT02700412 (adult arm) and NCT02695537 (pediatric arm)) published in the Epilepsy and Behavior
    • 01 Apr 2021 Results (n=169) assessing two year efficacy and safety of cannabidiol for epilepsy from two studies: NCT02700412 (adult arm) and NCT02695537 (pediatric arm) published in the Epilepsy and Behavior
    • 30 Mar 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top